Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

95.41EUR
15 Aug 2014
Price Change (% chg)

€-2.28 (-2.33%)
Prev Close
€97.69
Open
€97.78
Day's High
€98.45
Day's Low
€95.03
Volume
2,510,992
Avg. Vol
1,671,453
52-wk High
€106.90
52-wk Low
€83.72

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three business subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control,... (more)

Overall

Beta: 0.91
Market Cap (Mil.): €88,152.63
Shares Outstanding (Mil.): 826.95
Dividend: 2.10
Yield (%): 1.97

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 24.73 32.64 33.50
EPS (TTM): 4.31 -- --
ROI: 9.08 18.10 17.33
ROE: 18.35 18.80 18.19
Search Stocks

BRIEF-Bayer, Orion start phase III trial of prostate cancer agent

Sept 16 - Bayer AG : * Says initiates phase III trial of ODM-201 in men with high-risk

2:35am EDT

U.S. seeks to hold Bayer in contempt over product health claims

WASHINGTON - The American unit of Bayer AG is making unsubstantiated claims about its Phillips Colon Health product, the United States said on Friday as it sought to hold Bayer Corp in contempt of a court order for the statements.

12 Sep 2014

UPDATE 2-U.S. seeks to hold Bayer in contempt over product health claims

WASHINGTON, Sept 12 - The American unit of Bayer AG is making unsubstantiated claims about its Phillips Colon Health product, the United States said on Friday as it sought to hold Bayer Corp in contempt of a court order for the statements.

12 Sep 2014

Bayer seeks Japanese approval for Eylea injections

FRANKFURT - Germany's Bayer said it has submitted an application for Japanese marketing authorization of Eylea to treat patients with a buildup of fluid in the back of the eye caused by a blockage of veins in the retina.

04 Sep 2014

Bayer CropScience to invest $1 billion in U.S. by 2016

FRANKFURT - Bayer CropScience said it planned to invest close to $1 billion in the United States between 2013 and 2016 as it aimed to grow faster than the U.S. market as a whole.

03 Sep 2014

Bayer CropScience to invest $1 bln in USA by 2016

FRANKFURT, Sept 3 - Bayer CropScience plans to invest close to $1 billion in the United States between 2013 and 2016 to help it grow faster than the U.S. market, it said on Wednesday.

03 Sep 2014

Germany's Bayer to launch three new Xarelto trials

FRANKFURT - Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines.

29 Aug 2014

UPDATE 1-Germany's Bayer to launch three new Xarelto trials

* Bayer won't say whether it may raise peak sales estimate (Adds senior manager quotes, further details of trials)

29 Aug 2014

Germany's Bayer to launch three new Xarelto trials

FRANKFURT, Aug 29 - Germany's Bayer said it plans to launch three new studies to add more uses for its anti-clotting drug Xarelto, one of its top five new medicines.

29 Aug 2014

Fitch Assigns Bayer AG's Hybrid Notes 'BBB+', 50% Equity Credit; Affirms IDR at 'A'

(The following statement was released by the rating agency) LONDON, August 13 (Fitch) Fitch Ratings has assigned Bayer AG's EUR1.75bn and EUR1.5bn subordinated resettable floating-rate notes a rating of 'BBB+', two notches below Bayer's Issuer Default Rating (IDR) of 'A' in line with the existing hybrid notes. Fitch has applied a 50% equity credit to the two bonds, which are identical in ranking and terms with exception of maturity and pricing. Fitch has also affirmed Bayer's IDR at 'A' wit

13 Aug 2014

Earnings vs. Estimates

Search Stocks